Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19836468 | 1.00 | OPRL1 (0.32) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL18595802 | 1.00 | OPRL1 (0.32) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL22737517 | 0.89 | OPRL1 (0.34) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL24197073 | 0.89 | OPRL1 (0.34) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL11946723 | 0.84 | NCF1 (0.35) | OPRL1 | |
| SCHEMBL24697403 | 0.84 | OPRL1 (0.32) | OPRL1 | |
| SCHEMBL11946726 | 0.81 | OPRL1 (0.30) | OPRL1 | |
| SCHEMBL18898378 | 0.80 | — | — | |
| SCHEMBL92497 | 0.77 | — | — | |
| SCHEMBL22053982 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-11111233-B2 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2021-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | OPRL1 2046/4885OPRM1 2907/4885OPRD1 2485/4885 |
| US-11111233-B2 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity | LCK, WEE1, JAK1 | OPRL1 2978/4885OPRM1 3229/4885OPRD1 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.